Study of rifampicin resistance and comparison of dapsone resistance of M. leprae in pre- and post-MDT era

Indian Journal of Leprosy

Volumn 81, Issue 3, 2009, Pages 131-134

  Gupta, U D ^a   Katoch, K ^b,c   Katoch, V M ^d  

^a Animal Experiment Facility   (India)

^b Model Rural Health Research Unit   (India)

^c NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^d GOVERNMENT OF INDIA   (India)

Author keywords

Drug resistance; Leprosy; MDT

Indexed keywords

DAPSONE; RIFAMPICIN; LEPROSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; LEPROSY; MAJOR CLINICAL STUDY; MOUSE; MYCOBACTERIUM LEPRAE; NONHUMAN; PREVALENCE; RISK REDUCTION; SELF REPORT; TERTIARY HEALTH CARE; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; INDIA; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANIMALS; DAPSONE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; INDIA; LEPROSTATIC AGENTS; LEPROSY; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM LEPRAE; RIFAMPIN;

EID: 77953979875     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Almeida JG, Chacko CJ, Christian M et al (1983). DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk, South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results. Int J Lepr Other Mycobact Dis. 51: 366-373. (Pubitemid 14216841)
2. Balakrishnan S, Seshadri PS, Neelan PN et al (1983). Studies on sulphone resistant strains of M. leprae in field and institutionalized cases of leprosy. Lepr India. 55: 71-75. (Pubitemid 13034930)
3. Butlin CR, Neupane KD, Failbus SS et al (1996). Drug resistance in Nepali leprosy patients. Int J Lepr Other Mycobact Dis . 64 : 136-141. (Pubitemid 26255714)
4. Cambau E, Bonnafous P, Perani E et al (2002). Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis. 34: 39-45.
5. Cellona RV, Fajardo TT Jr, Kim DI et al (1990). Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, the Philippines, and Korea. Int J Lepr Other Mycobact Dis . 56: 1-11.
6. dela Cruz E, Cellona RV, Balagon MV et al (1996). Primary dapsone resistance in Cebu, The Philippines: causes for concern. Int J Lepr Other Mycobact Dis . 64: 253-256.
7. Desikan KV and Venkataramaniah HN (1976). A modified method of harvesting M. leprae from foot- pads of mice. Lepr India . 48: 157-162.
8. Guelpa-Lauras CC, Grosset JH, Constant-Desportes M et al (1984). Nine cases of rifampin - resistant leprosy. Int J Lepr Other Mycobact Dis. 52: 101-102. (Pubitemid 14137573)
9. Grosset JH, Guelpa-Lauras CC, Bobin P et al (1989). Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis. 57: 607-614.
10. Gupta UD, Katoch K, Natrajan M et al (1997). Viability detection of M. leprae: comparison of normal mouse foot pad and bacillary ATP bioluminescence assay. Acta Leprol. 10:209-212.
11. Hastings RC and Jacobson RR (1981). Rifampicin-resistant leprosy. Health Co-op Papers . 1: 47-54.
12. Jacobson RR and Hastings RC (1976). Rifampin- resistant leprosy. Lancet. 2: 1304-1305.
13. Ji B (1985). Drug resistance in leprosy-a review. Lepr Rev . 56: 265-278.
14. Kai M, Matsuoka M, Nakata N et al (1999). Diamino-diphenylsulfone resistance of Mycobacterium leprae due to mutations in the dihydropteroate synthase gene. FEMS Micobiol Lett.177 : 231-235.
15. Levy L, Shepard CC and Fasal P (1976). The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600,900 and 1200 mg; b) daily doses of 300 mg. Int J Lepr Other Mycobact Dis. 44: 183-187.
16. Maeda S, Matsuoka M, Nakata N et al (2001). Multidrug resistant Mycobacterium leprae from patients with leprosy. Antmicrob Agents Chemother. 45 : 3635-3639.
17. Matsuo Y, Tatsukawa H, Kim DI et al (1982). Primary dapsone-resistant leprosy in Republic of Korea. Int J Lepr Other Mycobact Dis. 50: 510. (Pubitemid 13094926)
18. Matsuoka M, Kashiwabara Y and Namisato M (2000). A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Int J Lepr Other Mycobact Dis. 68 : 452-455. (Pubitemid 32322345)
19. Pettit JHS and Rees RJW (1964). Sulphone resistance in leprosy: an experimental and clinical study. Lancet. 2: 673-674.
20. Shepard CC, Levy L and Fasal P (1974). Further experience with the bactericidal effect of rifampin on Mycobacterium leprae. Am J Trop Med Hyg. 23: 1120-1124.
21. Shetty VP, Uplekar MW and Antia NH (1996). Primary resistance to single and multiple drugs in leprosy-a mouse foot pad study. Lepr Rev. 67: 280-286.
22. Shetty VP, Wakade AV, Ghate S et al (2003). Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy. Int J Lepr Other Mycobact Dis. 71: 210-217.
23. Sreevatsa, Girdhar BK, Ramu G et al (1984). Parallel dapsone and rifampicin resistance : a prospective study. Nippon Rai Gakkai Zasshi. 53: 28-31.
24. Sreevatsa, Ramu G and Desikan KV (1985). Prevalence of drug resistance in Dharamapuri and a Pallipati areas of Tamil Nadu. Indian J Lepr. 57: 376-382.
25. World Health Organization (1977). Experts committee on leprosy-fifth report. WHO, Geneva, Switzerland. Tech Rep Ser, 607.
26. World Health Organization (1982). Chemotherapy of leprosy for control programmes. WHO, Geneva, Switzerland. Tech Rep Ser, 675.